Erasca

Cancer Therapies

Also 2 trials Clin1 solid tumors; ERAS-007 3 trials Clin2 multiple cancers, Clin0 NSCLC, GI tumors; ERAS-601 Clin1 solid tumors; ERAS-801 Clin1 malignant glioma (ODD); ERAS-3490 Clin0 solid tumors; 8 programs RD multiple cancers

Erasca is a precision oncology company with a clear mission: to erase cancer. Cancer is a genetic disease driven by mutations in different cellular pathways that promote uncontrolled cell growth. Erasca focuses on developing therapeutics for cancers driven by mutations in the RAS and MAPK pathway. To shut down the RAS/MAPK pathway, Erasca is pursuing small molecules, large molecules and protein degraders-alone, or in combination to target multiple nodes. This involves targeting RAS directly, upstream or downstream nodes or targeting escape routes. Erasca’s lead product candidates ERAS-007 and ERAS-601 have entered clinical trials for patients with solid tumors with several other programs in preclinical stage.